Navigation Links
SpectraScience Announces Updates
Date:10/28/2008

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today provided an update on the status of its business.

Jim Hitchin, SpectraScience's CEO, commented, "We have begun shipping our cancer detection devices to customers in both the United States and Europe. In addition, machines are now in place in leading research facilities throughout the country including the Mayo Clinic, San Diego VA Hospital, Minnesota Gastroenterology, P.A., the University of Southern California and the Boston University VA Hospital to gather the final data necessary to complete a study on the use of our WavSTAT(R) to detect cancer and pre-cancers of the esophagus. Esophageal cancer is deadly and its incidence is growing at a rate six times faster than that of all other solid tumor types. In the beginning phase of this trial there was greater than 90% sensitivity to detection of cancerous and pre-cancerous tissues and, therefore, we expect the follow-up final trial to be successful. The purpose of the final trial is to obtain a statistically significant sample size that will satisfy the FDA in a planned filing. We anticipate making this filing next year and, subject to approval, begin selling product in the United States immediately thereafter.

We now have the CE mark approval for our cancer and pre-cancer detection in the esophagus ahead of schedule in Europe. This means we will be able to start selling this product much earlier than anticipated, accelerating our revenue and cash flow. We have invested considerable effort internationally and receiving the CE mark is an important step in our progress.

A cornerstone of our business model is our focus on leveraging our existing technology to provide higher sensitivity for the screening of several deadly cancers. During 2009, we plan to begin preparing to submit an application for the use of our non-invasive technology to detect lung cancer. Lung cancer is a major illness annually affecting about 215,000 Americans and resulting in 162,000 deaths.

The Company continues its evolution in our recent transition from research and development to revenue generation, and we feel that we have the foundation built for a successful 2009. As the Company moves forward, we plan to focus our energies on sales and marketing initiatives. We believe SpectraScience is on a sound foundation as we continue to grow our business into a major contributor in the battle against cancer."

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval as an optical non-invasive system that has proven to be more effective in detecting cervical cancer precursors than conventional methods available in the market today.

Contacts:

SpectraScience

Jim Hitchin, Chief Executive Officer (858) 847-0200

Investor Relations

Todd M. Pitcher

Hayden Communications, Inc. (858) 518-1387

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. SpectraScience Awarded Patent for Correcting Image Misalignment
8. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some dirt on ... A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay into a ... the body. , A former motivational speaker, Perry A~ has since dedicated her life ...
(Date:2/8/2016)... Gaithersburg, MD (PRWEB) , ... February 08, 2016 ... ... (AHCC) is excited to share this important news! AHCC and the Home Health ... (AHA) Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to ...
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... Steven ... event he has completed every year since it started in 2003. This year, he ... the attention of fellow runners and NBA team the Miami Heat. , This Sunday, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Amgen (NASDAQ: ... Annual Global Healthcare Conference at 9:15 a.m. ET on ... . David W. Meline , executive vice president ... conference. Live audio of the presentation can be accessed from ... Investors. A replay of the webcast will also be available ...
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical ... aesthetic device company, announced today that William ... North America, is scheduled to participate in the ... Conference on February 11, 2016 in ... allow institutional investors to meet with the Mr. ...
(Date:2/5/2016)... CENTENNIAL, Colo. , Feb. 5, 2016  As ... about health. The multitude of recommended screenings and tests ... healthy aging a priority. However, for the majority of ... of proactive health planning. For the 37.5 million American ... time like the present to make hearing health a ...
Breaking Medicine Technology: